Immunohistochemical Evaluation of Vascular Endothelial Growth Factor (VEGF) in Splenic Hemangiomas and Hemangiosarcomas in Dogs

Abstract

Formation of new blood vessels is paramount for tumour growth and metastatic dissemination and vascular endothelial growth factor (VEGF) is one of the key regulators of this process. The purpose of this study was to evaluate the immunohistochemical expression of VEGF in 23 splenic hemangiosarcomas and 7 splenic hemangiomas in dogs. Blood tests performed previous to splenectomy were analysed for correlation with tumour VEGF expression. Results showed significantly higher VEGF expression in hemangiosarcomas than hemangiomas and lower hematocrit values and red cell count in dogs affected with malignant neoplasia (P < 0.05). These findings suggest the presence of high VEGF levels may be related to the malignant vascular proliferation seen in hemangiosarcomas.

Share and Cite:

A. Gianotti Campos, J. Alvares Duarte Bonini Campos, D. Soares Sanches, M. Lúcia Zaidan Dagli and J. Maria Matera, "Immunohistochemical Evaluation of Vascular Endothelial Growth Factor (VEGF) in Splenic Hemangiomas and Hemangiosarcomas in Dogs," Open Journal of Veterinary Medicine, Vol. 2 No. 4, 2012, pp. 191-195. doi: 10.4236/ojvm.2012.24030.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] N. Ferrara and T. Davis-Smyth, “The Biology of Vascular Endothelial Growth Factor,” Endocrine Reviews, Vol. 18, No 1, 2005, pp. 4-25. doi:10.1210/er.18.1.4
[2] B. Restucci, S. Papparella, P. Maiolino and G. De Vico, “Expression of Vascular Endothelial Growth Factor in Canine Mammary Tumors,” Veterinary Pathology, Vol. 39, No. 4, 2002, pp. 488-493. doi:10.1354/vp.39-4-488
[3] K. A. Houck, D. W. Leung, A. M. Bowland, J. Winer and N. Ferrara, “Dual Regulation of Vascular Endothelial Growth Factor Bioavailability by Genetic and Proteolytic Mechanisms,” The Journal of Biological Chemistry, Vol. 267, No. 36, 1992, pp. 26031-26037.
[4] A. Minchenko, T. Bauer, S. Salceda and J. Caro, “Hypoxic Stimulation of Vascular Endothelial Growth Factor Expression in Vitro and in Vivo,” Laboratory Investigation, Vol. 71, No. 3, 1994, pp. 374-379.
[5] S. R. Platt, T. J. Scase, V. Adams, L. Wieczorek, J. Miller, F. Adamo and S. Long, “Vascular Endothelial Growth Factor Expression in Canine Intracranial Meningiomas and Association with Patient Survival,” Journal of Veterinary Internal Medicine, Vol. 20, No. 3, 2006, pp. 663-668. doi:10.1111/j.1939-1676.2006.tb02912.x
[6] N. Weidner, J. P. Semple and W. R. Welch, “Tumor Angiogenesis and Metastasis Correlation in Invasive Breast Carcinoma,” New England Journal of Medicine, Vol. 324, No. 1, 1991, pp. 1-8. doi:10.1056/NEJM199101033240101
[7] E. Y. Soh, S. A. Sobhi, M. G.Wong, Y. G. Meng, A. E Siperstein, O. H. Clark and Q. Duh, “Thyroid-Stimulating Hormone Promotes the Secretion of Vascular Endothelial Growth Factor in Thyroid Cancer Cell Lines,” Surgery, Vol. 120, No. 6, 1996, pp. 944-947. doi:10.1016/S0039-6060(96)80038-9
[8] R. S. Warren, H. Yuan, M. R. Matli, N. Ferrara and D. B.Donner, “Induction of Vascular Endothelial Growth Factor by Insulin-Like Growth Factor 1 in Colorectal Carcinoma,” The Journal of Biological Chemistry, Vol. 271, No. 46, 1996, pp. 29483-29488. doi:10.1074/jbc.271.46.29483
[9] P. Borgstrom, M. A. Bourdon, K. J. Hillan, P. Sriramarao and N. Ferrara, “Neutralizing Anti-Vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors in Vivo,” The Prostate, Vol. 35, No. 1, 1998, pp. 1-10. doi:10.1002/(SICI)1097-0045(19980401)35:1<1::AID-PROS1>3.0.CO;2-O
[10] A. N. Al-Dissi, D. M. Haines, B. Singh and B. S.Kidney, “Immunohistochemical Expression of Vascular Endothelial Growth Factor and vascular Endothelial Growth Factor Receptor in Canine Cutaneous Fibrossarcomas,” Journal of Comparative Pathology, Vol. 141, No. 4, 2009, pp. 229-236. doi:10.1016/j.jcpa.2009.05.004
[11] F. Millanta, V. Caneschi, L. Ressel, S. Citi and A. Poli, “Expression of Vascular Endothelial Growth Factor in Canine Inflammatory and Non-Inflammatory Mammary Carcinoma,” Journal of Comparative Pathology, Vol. 142, No. 1, 2010, pp. 36-42. doi:10.1016/j.jcpa.2009.06.004
[12] R. Chun and D. H. Thamm, “Targeting Angiogenesis and Tumor Vasculature,” In: S. J. Withrow and D. M. Vail, Eds., Small Animal Clinical Oncology, Saunders Elsevier, St Louis, 2007. p. 259-266.
[13] S. Sabattini and G. Bettini, “An Immunohistochemical Analysis of Canine Haemangioma and Haemangiosarcoma,” Journal of Comparative Pathology, Vol. 140, No. 2-3, 2009, pp. 158-168. doi:10.1016/j.jcpa.2008.10.006
[14] N. Uchida, K. Nagai, Y. Sakurada and K. Shirota, “Distribution of Vegf and flt-1 in the Normal Dog Tissues,” The Journal of Veterinary Medical Science, Vol. 70, No. 11, 2008, pp. 1273-1276. doi:10.1292/jvms.70.1273
[15] K. Yonemaru, H. Sakai, M. Murakami, T. Yanai T. and Masegi, “Expression of Vascular Endothelial Growth Factor, Basic Fibroblast Growth Factor, and Their Receptors (flt-1, flk-1, and flg-1) in Canine Vascular Tumors,” Veterinary Pathology, Vol. 43, No. 6, 2006, pp. 971-980. doi:10.1354/vp.43-6-971
[16] C. A. Clifford, D. Hughes, M. W. Beal, A. J. Mackin, C. J. Henry, F. S. Shofer and K.U. Sorenmo, “Plasma Vascular Endothelial Growth Factor Concentrations in Healthy Dogs and Dogs with Hemangiosarcoma,” Journal of Veterinary Medicine, Vol. 15, No. 2, 2001, pp. 131-135.
[17] G. C. Troy, W. R. Huckle, J. H. Rossmeis, D. Panciera, O. Lanz, J. L.Robertson and D. L.Ward, “Endostatin and Vascular Endothelial Growth Factor Concentrations in Healthy Dogs, Dogs with Selected Neoplasia, and Dogs with Nonneoplastic Diseases,” Journal of Veterinary Internal Medicine, Vol. 20, No. 1, 2006, pp.144-150. doi:10.1111/j.1939-676.2006.tb02834.x

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.